Meet Our Students

Read profiles of our PhD students to learn about their experience and research. 

More Information

The Columbia University Department of Systems Biology invites applications from students interested in pursuing careers at the frontiers of modern biology. You will learn to apply powerful, multidisciplinary approaches and address critical biological questions from the perspective of complex genomic and molecular systems.

PhD education at Columbia stresses the importance of high-throughput experimentation, quantitative analysis of large biological data sets, and innovative technology development. Whether your primary interest is in experimental or computational research in systems biology, the experience you gain will prepare you to participate in cutting-edge science that integrates the two.

More Information

This year’s application deadline is December 1, 2018.

News

Why Some Brain Tumors Respond to Immunotherapy
Fewer than 1 in 10 patients with glioblastoma­ respond to immunotherapy, which has shown remarkable success in the past few years in treating a variety of aggressive cancers. But there has been no way to know in advance which glioblastoma patients will respond. In a study, led by Raul Rabadan, PhD, researches have learned why some glioblastomas—the most common type of brain cancer—respond to immunotherapy. The findings could help identify patients who are most likely to benefit from treatment with immunotherapy drugs and lead to the development of more broadly effective treatments.
Prostate Cancer Grant Spotlights Columbia’s Aim to Deliver Precision Cancer Medicine
Columbia University Irving Medical Center experts in prostate cancer will lead a new team research project that tests a novel approach for personalized cancer treatment. The two-year project, funded by a $1 million Challenge Award from the Prostate Cancer Foundation, combines computational methods for targeted drug therapy, single-cell RNA sequencing and novel cancer immunotherapy. The combined approaches are behind a proof-of-concept clinical trial for patients at Bronx VA with lethal metastatic prostate cancer.